SLXN Silexion Therapeutics Corp
$0.36▼ -15.43%
Healthcare
Other
After hours
$0.33▼ -6.75%
Sep 11, 7:57 PM ET
Volume 2.58M
Avg Volume (10D) 12.27M
Key Metrics & Fundamentals
Market Cap
$1.99M
P/E Ratio
–
Div Yield
–%
52W Range
0.34 - 42.60
% vs 50 MA
-75.15%
% vs 200 MA
-96.74%
RSI-14
25.1
MACD Histogram
+0.0800
Beta (1Y vs SPY)
3.09
Free Cash Flow
-$2.93M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$3.64M
COGS
–
Operating Exp
$3.68M
Operating Income
-$3.68M
EBIT
-$3.68M
Pretax Income
-$3.55M
Net Income
-$3.55M
EPS (Diluted)
-5.17
Price & Volume History
Loading chart…
Recent News
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
GlobeNewswire · Sep 9, 2026 1:00 PM
Silexion Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · Aug 14, 2026 12:45 PM
Top Premarket Decliners
MT Newswires · Aug 12, 2026 11:22 AM
Silexion Therapeutics Announces Pricing of $2.5 Million Public Offering
GlobeNewswire · Aug 12, 2026 12:01 AM
Silexion Therapeutics Reports New Positive Preclinical Findings Demonstrating Multi-Mechanism Immune Sensitization by SIL204 in KRAS-Driven Cancers
GlobeNewswire · Aug 4, 2026 1:15 PM
Silexion Therapeutics Successfully Initiates Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer at Tel Aviv Sourasky Medical Center
GlobeNewswire · Jul 29, 2026 11:00 AM
Silexion Therapeutics Receives Approval from Germany's BfArM to Initiate Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
GlobeNewswire · Jun 23, 2026 12:40 PM
Silexion Therapeutics to Attend BIO International Convention 2026
GlobeNewswire · Jun 16, 2026 8:30 PM
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See SLXN's money flow as a full page
Social Sentiment
Avg +0.70 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.